Table 2 In vivo efficacy of ABT-737 in... | American Society of Hematology

Table 2

In vivo efficacy of ABT-737 in combination with VXL

	ALL-7		ALL-19
	Median EFS, d (range)	LGD, d	Median EFS, d (range)	LGD, d
Control	10.4 (6.6-18.3)	—	14.0 (10.2-22.0)	—
VXL	82.0* (76.6-102.1)	71.6	50.5* (45.4-56.7)	36.5
ABT-737	37.0* (34.5-43.2)	26.6	16.6† (9.0-48.0)	2.6
VXL/ABT-737	128.9*‡§ (25.9-191)	118.5	81.7*†‖ (46.2-85.1)	67.7

	ALL-7		ALL-19
	Median EFS, d (range)	LGD, d	Median EFS, d (range)	LGD, d
Control	10.4 (6.6-18.3)	—	14.0 (10.2-22.0)	—
VXL	82.0* (76.6-102.1)	71.6	50.5* (45.4-56.7)	36.5
ABT-737	37.0* (34.5-43.2)	26.6	16.6† (9.0-48.0)	2.6
VXL/ABT-737	128.9*‡§ (25.9-191)	118.5	81.7*†‖ (46.2-85.1)	67.7

— indicates not applicable.

Relative to control, P≤ .001.

Relative to VCR/DEX/L-ASP, P = .001.

Relative to VCR/DEX/L-ASP, P = .020.

Relative to ABT-737, P = .015.

Relative to ABT-737, P < .001.